CD200 and breast cancer: Using TISIBD, we also noticed that the levels of CD200 and CD276 expression were higher in the TGF‐β dominant subtype of breast cancer (Figure 4E and G) which was enriched with TGF‐β signature and lymphocytic infiltrate but suffered the worst overall survival29 than in other immune subtypes.